KR930013112A - 바이러스성 항원을 이용한 특이적 면역원의 발현 - Google Patents
바이러스성 항원을 이용한 특이적 면역원의 발현 Download PDFInfo
- Publication number
- KR930013112A KR930013112A KR1019920023656A KR920023656A KR930013112A KR 930013112 A KR930013112 A KR 930013112A KR 1019920023656 A KR1019920023656 A KR 1019920023656A KR 920023656 A KR920023656 A KR 920023656A KR 930013112 A KR930013112 A KR 930013112A
- Authority
- KR
- South Korea
- Prior art keywords
- epitope
- polypeptide
- protein
- vaccine
- amino acid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract 7
- 102000036639 antigens Human genes 0.000 title claims abstract 7
- 108091007433 antigens Proteins 0.000 title claims abstract 7
- 230000003612 virological effect Effects 0.000 title claims 4
- 241000712431 Influenza A virus Species 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 12
- 230000000890 antigenic effect Effects 0.000 claims abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 11
- 239000002773 nucleotide Substances 0.000 claims abstract 10
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 10
- 229960005486 vaccine Drugs 0.000 claims abstract 9
- 239000012634 fragment Substances 0.000 claims abstract 7
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract 5
- 239000013604 expression vector Substances 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 239000012636 effector Substances 0.000 claims 6
- 102200020671 rs121912988 Human genes 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 102000018697 Membrane Proteins Human genes 0.000 claims 4
- 108010077805 Bacterial Proteins Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 102220350531 c.80A>G Human genes 0.000 claims 3
- 102200061298 rs1064795967 Human genes 0.000 claims 3
- 102220323264 rs777883490 Human genes 0.000 claims 3
- 229940037003 alum Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical group OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims 1
- 229960005225 mifamurtide Drugs 0.000 claims 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 102400000368 Surface protein Human genes 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 101150039660 HA gene Proteins 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
5개의 면역지배 항원성 부위를 갖는 인플루엔자 A 바이러스의 HA 표면 단백질을 암호화하는 뉴클레오타이드 서열과 실질적으로 같은 뉴클레오타이드 서열(여기에서, 외래성 에피톱을 암호화하는 뉴틀레오타이드 서열과 실질적으로 같은 뉴틀레오타이드)을 함유하는 키메릭 DNA 단편이 제공된다. 이에 상응하는 키메릭 펩타이드, 발현벡터, 및 형질전환된 숙주도 제공된다. 이를 펩타이드는 항원에 대한 백신으로 제조하는데 이러한 항원에의 노출을 검출하는 시험 키트에 사용된다.
또한, 이들 펩타이드는 면역치료법을 포함하여, 이러한 항원에의 노출증상을 치료 및 예방하는 데에 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 인플루엔자 A 바이러스의 HA 단백질 모형이다.
제2도는 HA 유전자의 bp498위치(aa139에 상응하는 위치)에 Apal 부위를 갖는 HA 유전자에, 한 예료서 HIV 에피톱을 삽입하는 과정을 도시화한 것이다.
Claims (27)
- 5개의 면역지배(immonodominant)항원성 부위를 갖는 인플루엔자 A 바이러스의 HA 표면 단백질을 암호화하는 뉴클레오타이드 서열과 실질적으로 같은 뉴클레오타이드 서열(여기에서, IgE 효과기(effector)부위 에피톱, 세균성 단백질 에피톱, 종양성 에피톱, SP10 에피톱 또는, T20E, T16G, D18S, G20E, K27R, E14Q, N22G, p17, p24, gp160및 gp120으로 구성된 그룹에서 선택된 HIV 바이러스 에피톱을 암호화하는 뉴틀레오타이드 서열과 실질적으로 같은 뉴클레오타이드 서열이 하나 이상의 항원성 부위를 암호화하는 뉴클레오타이드 서열내로 삽입된다)을 합유하는 DNA 단편.
- 제1항에 있어서, 항원성 부위가 HA 단백질의 A 영역인 DNA 단편.
- 제1항에 있어서, 항원성 부위가 HA 단백질의 아미노산 183-192에 상응하는 DNA 단편.
- 제1항에 있어서, 삽입된 뉴클레오타이드 서열이 HIV 바이러스 에피톱인 N22G, D18S 또는 T16G중 하나를 암호화하는 것인 DNA 단편.
- 제4항에 있어서, 삽입된 뉴클레오타이드 서열이 HIV 바이러스 에피톱인 N22G를 암호화하는 DNA 서열.
- 제1항에 있어서, 삽입된 뉴클레오타이드 서열이 IgE 효과기 부위 에피톱, K10F 또는 H22V중 하나를 암호화하는 것인 DNA 단편.
- 5개의 면역지배 항원성 부위를 갖는 인플루엔자 A 바이러스의 HA 표면 단백질과 실질적으로 같은 아미노산 서열(여기에서, IgE 효과기(effector)부위 에피톱, 세균성 단백질 에피톱, 종양성 에피톱, SP10 에피톱 또는, T20E, T16G, D18S, G20E, K27R, E14Q, N22G, p17, p24, gp160및 gP120으로 구성된 그룹에서 선택된 HIV바이러스 에피톱의 아미노산 서열과 실질적으로 같은 아미노산 서열이 하나 이상의 항원성 부위에 대한 아미노산 서열내로 삽입된다)을 함유하는 폴리펩타이드.
- 제7항에 있어서, 항원성 부위가 HA 단백질의 A 영역인 폴리펩타이드.
- 제7항에 있어서, 항원성 부위가 HA 단백질의 아미노산 183-192에 상응하는 폴리펩타이드.
- 제7항에 있어서, 삽입된 아미노산 서열이 HIV 바이러스 에피톱인 N22G, D18S 또는 T16G인 폴리펩타이드.
- 제10항에 있어서, 삽입된 아미노산 서열이 N22G인 폴리펩타이드.
- 제7항에 있어서, 삽입된 아미노산 서열이 IgE 효과기 부위 에피톱, K10F 또는 H22V중 하나인 폴리펩타이드.
- 인플루엔자 A 바이러스의 HA 표면 단백질의 아미노산 서열을 지닌 폴리펩타이드(여기에서, 5개의 면역지배 항원성 부위중 하나이상이, IgE 효과기 부위 에피톱, 세균성 단백질 에피톱, SP10 에피톱 또는, T20E, T16G, D18S, G20E, K27R, E14Q, N22G, P17, P24, gp160, 및 gp120으로 구성된 그룹에서 선택된 HIV 바이러스 에피로으로 구성된 그룹에서 선택된 외래성 에피톱 삽입체 하나를 갖는다)를 보조제와 함께 함유하는 백신.
- 제13항에 있어서, 외래성 에피톱이 HA 표면 단백질의 항원성 A 영역에 삽입된 백신.
- 제13항에 있어서, 삽입체가 HIV 바이러스 에피톱인 N22G, D18S 또는 T16G인 백신.
- 제13항에 있어서, 삽입체가 N22G인 백신.
- 제13항에 있어서, 삽입체가 IgE 효과기 부위 에피톱, K10F 또는 H22V인 백신.
- 제13항에 있어서, 보조제가 신텍스(Syntex)보조제, 알룸(alum), 면역자극복합체, 파상풍 특소이드, 디프테리아톡소이드, 보조제 글리코시드 퀼(Quil) A, 저유 에멀젼(low oil emulsion)중의 무라밀 디펩타이드 유도체(MTP-PE), 및 바람직하게는 콜레스테릴헤미숙시네이트-기본 리포좀인 백신.
- 제13항에 있어서, 상기 보조제가 신텍스 보조제 또는 알룸인 백신.
- 제1항의 DNA 단편을 함유하는 게놈을 갖는 재조합 바률로바이러스를 함유하는 발현 벡터.
- 제20항의 발현벡터로 형질전환시킨 미생물.
- 제20항의 발현벡터로 형질전환시킨 곤충세포.
- 제7항의 폴리펩타이드에 대하여 포유동물내에서 유도된 폴리펩타이드 특이적 항체를 함유하는, 바이러스성, 세균성 또는 종양성 항원의 존재검출용 제제.
- 제13항의 백신 유효량을 투여함을 특징으로 하여, 포유동물의 HIV 감염증을 치료 또는 예방하는 방법.
- 제13항의 백신 유효량을 투여함을 특징으로 하여, 포유동물의 알레르기 반응을 치료 또는 예방하는 방법.
- 제7항의 단백질을 숙주에 노출시킴으로써 유도시킨 항체 유효량을 투여함을 특징으로 하여, 포유동물의 감염증 또는 병리학적 증상을 치료 또는 예방하는 방법.
- 포유동물의 혈액 샘플 또는 이의 분획을 제23항의 폴리펩타이드 유효 항원 검출량과 접촉시키고, 생성된 항원/항체 복합체의 존재여부 및 함량을 측정함을 특징으로 하여 포유동물의 바이러스성, 세균성 또는 종양성 항원을 검출하는 방법.참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80510591A | 1991-12-11 | 1991-12-11 | |
| US07/805,105 | 1991-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930013112A true KR930013112A (ko) | 1993-07-21 |
Family
ID=25190685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920023656A KR930013112A (ko) | 1991-12-11 | 1992-12-09 | 바이러스성 항원을 이용한 특이적 면역원의 발현 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5591823A (ko) |
| EP (1) | EP0546787A3 (ko) |
| JP (1) | JPH05262667A (ko) |
| KR (1) | KR930013112A (ko) |
| CN (1) | CN1073878A (ko) |
| AU (1) | AU2981992A (ko) |
| BR (1) | BR9204978A (ko) |
| CA (1) | CA2084180A1 (ko) |
| CZ (1) | CZ362692A3 (ko) |
| FI (1) | FI925590A (ko) |
| HU (2) | HUT65366A (ko) |
| IL (1) | IL103928A0 (ko) |
| MX (1) | MX9207113A (ko) |
| NO (1) | NO924780L (ko) |
| SK (1) | SK362692A3 (ko) |
| TW (1) | TW239162B (ko) |
| ZA (1) | ZA929355B (ko) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69333433T2 (de) * | 1992-04-01 | 2004-12-02 | The Rockefeller University | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
| CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| WO1995007099A1 (fr) * | 1993-09-09 | 1995-03-16 | The Nisshin Oil Mills, Ltd. | Vaccin et procede pour sa production |
| ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
| US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| EP2374894B1 (en) * | 1993-09-13 | 2014-09-17 | Protein Sciences Corporation | A method for producing influenza hemagglutinin multivalent vaccines |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| EP1275726B1 (en) * | 1995-05-26 | 2008-02-20 | Mg-Pmc, L.L.C. | A method for producing influenza hemagglutinin multivalent vaccines |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| AU7471098A (en) * | 1997-04-30 | 1998-11-24 | Mount Sinai School Of Medicine Of The City University Of New York, The | Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents |
| US6274378B1 (en) | 1997-10-27 | 2001-08-14 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
| WO1999042564A2 (en) | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| WO2002026252A1 (fr) * | 2000-08-10 | 2002-04-04 | Tsinghua University | Vaccin contre le virus de la grippe et son procede de preparation |
| EP1318922B1 (en) | 2000-09-11 | 2004-11-03 | Dow Global Technologies Inc. | Method of manufacturing a run flat tire support |
| EP1610757A4 (en) * | 2003-04-10 | 2007-05-30 | Transform Pharmaceuticals Inc | PROFILING OF CONFORMATIONAL VARIANTS, ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF |
| KR20080027777A (ko) * | 2005-06-01 | 2008-03-28 | 배리에이션 바이오테크놀로지스 아이엔씨. | 펩티드기초 인플루엔자 백신 제제 |
| EP1989326A4 (en) | 2006-01-17 | 2009-09-30 | Health Research Inc | HETERO DUPLEX TRACKING TEST |
| TWI438207B (zh) * | 2007-02-21 | 2014-05-21 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| NZ592461A (en) | 2008-10-22 | 2012-12-21 | Oncotherapy Science Inc | Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| CN101708442B (zh) * | 2009-09-04 | 2011-08-24 | 山东中惠仪器有限公司 | 全自动标准气体配制装置 |
| EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10063211B2 (en) * | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| CN114634916A (zh) * | 2016-02-03 | 2022-06-17 | Cg探索股份有限公司 | 具有异源表位和/或改变的成熟切割位点的流感血凝素的组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339504A3 (en) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
| US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| EP0492920A1 (en) * | 1990-12-24 | 1992-07-01 | Merck & Co. Inc. | Chimaeric influenza-HIV vaccine |
-
1992
- 1992-11-30 CA CA002084180A patent/CA2084180A1/en not_active Abandoned
- 1992-11-30 IL IL103928A patent/IL103928A0/xx unknown
- 1992-12-01 JP JP4321768A patent/JPH05262667A/ja active Pending
- 1992-12-02 AU AU29819/92A patent/AU2981992A/en not_active Abandoned
- 1992-12-02 ZA ZA929355A patent/ZA929355B/xx unknown
- 1992-12-07 EP EP19920311146 patent/EP0546787A3/en not_active Withdrawn
- 1992-12-07 TW TW081109778A patent/TW239162B/zh active
- 1992-12-09 MX MX9207113A patent/MX9207113A/es unknown
- 1992-12-09 KR KR1019920023656A patent/KR930013112A/ko not_active Application Discontinuation
- 1992-12-09 FI FI925590A patent/FI925590A/fi not_active Application Discontinuation
- 1992-12-10 CZ CS923626A patent/CZ362692A3/cs unknown
- 1992-12-10 CN CN92113703A patent/CN1073878A/zh active Pending
- 1992-12-10 NO NO92924780A patent/NO924780L/no unknown
- 1992-12-10 SK SK3626-92A patent/SK362692A3/sk unknown
- 1992-12-10 BR BR9204978A patent/BR9204978A/pt not_active Application Discontinuation
- 1992-12-11 HU HU9203931A patent/HUT65366A/hu unknown
-
1993
- 1993-12-17 US US08/169,813 patent/US5591823A/en not_active Expired - Lifetime
-
1995
- 1995-06-27 HU HU95P/P00456P patent/HU211548A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO924780L (no) | 1993-06-14 |
| SK362692A3 (en) | 1995-11-08 |
| US5591823A (en) | 1997-01-07 |
| MX9207113A (es) | 1994-05-31 |
| EP0546787A2 (en) | 1993-06-16 |
| IL103928A0 (en) | 1993-04-04 |
| FI925590A0 (fi) | 1992-12-09 |
| CA2084180A1 (en) | 1993-06-12 |
| CN1073878A (zh) | 1993-07-07 |
| CZ362692A3 (en) | 1994-02-16 |
| HU9203931D0 (en) | 1993-04-28 |
| NO924780D0 (no) | 1992-12-10 |
| BR9204978A (pt) | 1993-06-15 |
| ZA929355B (en) | 1994-06-02 |
| EP0546787A3 (en) | 1994-06-01 |
| HU211548A9 (en) | 1995-12-28 |
| FI925590A (fi) | 1993-06-12 |
| HUT65366A (en) | 1994-05-02 |
| TW239162B (ko) | 1995-01-21 |
| AU2981992A (en) | 1993-06-17 |
| JPH05262667A (ja) | 1993-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930013112A (ko) | 바이러스성 항원을 이용한 특이적 면역원의 발현 | |
| JP5814331B2 (ja) | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 | |
| KR870000702B1 (ko) | 합성 항원 펩티드의 제조방법 | |
| AU2001282706B2 (en) | HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines | |
| KR910012233A (ko) | 칠면조의 재조합 포진바이러스와 그것에서 유도한 생존상태의 벡터 백신류 | |
| KR960703136A (ko) | 탠덤 합성 hiv-1 펩티드들 | |
| AU2001282706A1 (en) | HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines | |
| KR20130041185A (ko) | 디자이너(designer) 펩티드-기반 pcv2 백신 | |
| AU2001286336B2 (en) | HIV peptides from Tat, Rev and Wef conserved and their application as E.G. vaccine components | |
| US7056519B2 (en) | Methods for inducing HIV-neutralizing antibodies | |
| CA2338886A1 (en) | Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response | |
| JP2656521B2 (ja) | ネコ白血病ウイルス抗原の製造法と用途 | |
| JPS63254983A (ja) | エイズの病原であるウイルスのｐ２５蛋白質をコードするウイルスベクター及び組換ＤＮＡ、感染された細胞培養物、得られる蛋白質、ワクチン及び得られる抗体 | |
| EP0293792A2 (en) | Human immunodeficiency virus GAG-encoded proteins | |
| AU2004200155C1 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| AU2006235987B2 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| KR0142210B1 (ko) | 돼지파보바이러스 vp2 단백질의 대량 생산방법 및 돼지파보바이러스 감염증용 백신용 백신의 제조방법 | |
| Wong | The development of the Pseudomonas aeruginosa outer membrane protein OprF as a presentation vector for foreign antigenic determinants | |
| RU92004487A (ru) | Днк, полипептид, вакцина, вектор, микроорганизм, клетка насекомого, реагент, способы лечения и профилактики, способ обнаружения антигенов | |
| WO2001029177A2 (en) | Hiv-1 subtype d peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |